Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Investigational topical nonsteroidal androgen-receptor antagonist

Pyrilutamide — evidence

What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.

Evidence overview

2 records in this file

  • CLINICAL TRIAL2

Research areas. Investigational hair-follicle research.

Publication span. 2022–2024.

What we know

    Editorial reading of the records below, labelled as Therapept analysis. How records are built

    What remains uncertain

      Regulatory notes

      Investigational

      • No approved United States product in Drugs@FDA as of this review.
      • Phase 2 trial NCT05218642 randomised 123 men in the United States and is registered as completed.
      • Phase 3 trial NCT06126965 in Chinese adult men is registered with an actual enrolment of 740 participants.
      • Phase 2 trial NCT06409650 in Chinese adult women randomised 160 participants and is registered as completed.
      • Registry completion is not a published result and not an approval. Therapept has not indexed a peer-reviewed primary publication of the Phase 3 results.

      Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.

      Studies and documents

      1. CLINICAL TRIAL2024Phase 3 randomised, double-blind, placebo-controlled trial (registry record)

        Phase III study of KX-826 in Chinese adult male patients with androgenetic alopecia

        Suzhou Kintor Pharmaceutical IncClinicalTrials.gov

        Population
        Chinese adult men with androgenetic alopecia
        Sample
        n = 740 (actual enrolment)
        Objective
        To evaluate the efficacy and safety of topical KX-826 5% in Chinese adult men with androgenetic alopecia.
        Endpoint investigated
        Target-area hair count and investigator- and patient-assessed hair growth over 24 weeks

        Study design

        Registry
        NCT06126965

        This describes the published study design. It is not a usage or dosing recommendation.

        The registry record describes a Phase 3, multicentre, randomised, double-blind, placebo-controlled trial with 740 participants and 26 sites in China. Hair-growth assessments were scheduled through 24 weeks.

        Limitations. Registry record only. Therapept has not indexed a peer-reviewed publication of the Phase 3 results, and a registered or completed trial is not an approval.

        ClinicalTrials.gov — NCT06126965Reviewed 13 November 2026

      2. CLINICAL TRIAL2022Phase 2 randomised, double-blind, placebo-controlled trial (registry record)

        Phase 2 study of KX-826 in male subjects with androgenetic alopecia

        Suzhou Kintor Pharmaceutical IncClinicalTrials.gov

        Population
        Adult men with androgenetic alopecia
        Sample
        n = 123
        Objective
        To evaluate the efficacy, safety and tolerability of topical KX-826 in men with androgenetic alopecia.
        Endpoint investigated
        Change from baseline in non-vellus target-area hair count at week 24 versus placebo

        Study design

        Registry
        NCT05218642

        This describes the published study design. It is not a usage or dosing recommendation.

        The registry record describes a randomised, double-blind, placebo-controlled Phase 2 study of topical KX-826 in 123 men, with non-vellus target-area hair count at week 24 as the primary endpoint. The record is listed as completed.

        Limitations. Registry record only. No peer-reviewed primary report of this trial is indexed here, and completion is not evidence of efficacy or an approval.

        ClinicalTrials.gov — NCT05218642Reviewed 13 November 2026

      Last reviewed 13 November 2026 · Compiled by Therapept Editorial · How these records are built